Abstract
Aerosols and droplets generated from expiratory events play a critical role in the transmission of infectious respiratory viruses. Increasingly robust evidence has suggested the crucial role of fine aerosols in airborne transmission of respiratory diseases, which is now widely regarded as an important transmission path of COVID-19. In this report, we used CFD modelling to investigate the efficiency of using portable air purifiers containing HEPA filters to reduce airborne aerosols in hospitals and serve as a potential retrofit mitigation strategy. We used a consulting room to set up our simulations because currently the clearance time between consultations is the controlling factor that limits the patient turnover rate. The results suggest the inlet/suction of the air purifier unit should be lifted above the floor to achieve better clearance efficiency, with up to 40% improvement possible. If multiple air purifiers are used, the combined efficiency can increase to 62%. This work provides practical guidance on a mitigation strategy that can be easily implemented in an expedient, cost-effective and rapid manner, and paves the way for developing more science-informed strategies to mitigate the airborne transmission of respiratory infections in hospitals.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by UCLH Charity (ref: 7243) and the NICEDROPS project supported by the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme under grant agreement no. 714712.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
This article has no additional data.
